Table I.
Patient Characteristics
| Stem Cell Dose | ||||
|---|---|---|---|---|
| High (n = 41) | Standard (n = 39) | P-value | ||
| Median age at ASCT (range) | 65 (37–75) | 64 (42–79) | .82 | |
| Median cell dose, × 106 CD34+ cells/kg (range) | 10.5 (5.5–18.8) | 5.1 (3.5–11.1) | < .0001 | |
| Female (%) | 12 (29.3) | 13 (33.3) | .70 | |
| International Staging System (ISS) stage (%) | .95 | |||
| Unknown | 10 (24.4) | 10 (25.6) | ||
| I | 12 (29.3) | 13 (33.3) | ||
| II | 12 (29.3) | 11 (28.2) | ||
| III | 7 (17.0) | 5 (12.8) | ||
| ECOG performance status at baseline | .17 | |||
| 0 | 9 (22.0) | 13 (33.3) | ||
| 1 | 29 (77.7) | 25 (64.1) | ||
| 2 | 3 (7.3) | 0 (0) | ||
| 3 | 0 (0) | 1 (2.6) | ||
| Evidence of AL amyloidosis* (%) | 14 (34.15%) | 8 (21.05%) | .19 | |
| Poor risk cytogenetics (%) | 7 (17.95%) | 3 (8.57%) | .24 | |
| Induction regimen | ||||
| VD | 13 (31.7%) | 12 (30.8%) | .43 | |
| RD | 1 (2.4%) | 9 (23.1%) | .01 | |
| CyBorD | 7 (17.0%) | 5 (12.9%) | .35 | |
| VRD | 5 (12.2%) | 5 (12.9%) | 1.00 | |
| CVAD | 1 (2.4%) | 0 | NA | |
| VTD or TD | 6 (14.6%) | 1 (2.6%) | .104 | |
| Mobilization regimen | ||||
| G-CSF alone | 27 (65.8%) | 29 (74.3%) | .63 | |
| Cyclophosphamide-based chemomobilization | 8 (19.5%) | 7 (17.9%) | 1.00 | |
| Plerixafor and G-CSF | 6 (14.6%) | 4 (10.3%) | .74 | |
| Response prior to transplant | ||||
| CR | 1 (2.4%) | 1 (2.6%) | 1.00 | |
| VGPR | 13 (31.7%) | 20 (51.3%) | .11 | |
| PR | 19 (46.3 %) | 11 (28.2%) | .16 | |
| SD | 7 (17.05) | 6 (15.3%) | 1.00 | |
| PD | 1 (2.4%) | 1 (2.6%) | 1.00 | |
Abbreviations: ASCT, autologous hematopoietic stem cell transplant; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; G-CSF, granulocyte colony stimulating factor; VD, bortezomib-dexamethasone; RD, lenalidomide-dexamethasone; CyBorD, cyclophosphamide-bortezomib-dexamethasone; VRD, bortezomib-Lenalidomide-dexamethasone; CVAD, cyclophosphamide-vincristine-doxorubicin-dexamethasone; VTD, bortezomib-thalidomide-dexamethasone; TD, thalidomide-dexamethasone.
*
Evidence of AL amyloidosis was defined by a biopsy showing light chain amyloid deposition at any site.